These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

497 related articles for article (PubMed ID: 10629651)

  • 21. [Clinical usefulness of serum assay of EIA-CYFRA 21-1 in lung cancer].
    Satoh H; Yagyu H; Sumi M; Ishikawa H; Hamada M; Suyama T; Naitoh T; Inoue M; Saitoh T; Uchida Y
    Gan To Kagaku Ryoho; 1994 May; 21(6):795-9. PubMed ID: 7514388
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cytokeratin 19 fragment CYFRA 21-1 compared with carcinoembryonic antigen, squamous cell carcinoma antigen and neuron-specific enolase in lung cancer. Results of an international multicentre study.
    Ebert W; Dienemann H; Fateh-Moghadam A; Scheulen M; Konietzko N; Schleich T; Bombardieri E
    Eur J Clin Chem Clin Biochem; 1994 Mar; 32(3):189-99. PubMed ID: 7518259
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of CYFRA 21-1 and tissue polypeptide specific antigen (TPS) for detecting nasopharyngeal carcinoma.
    Tai CJ; Liu FY; Liang JA; Yang SN; Tsai MH; Kao CH
    Anticancer Res; 2002; 22(6B):3793-6. PubMed ID: 12552995
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Utility of serum cytokeratin 19 fragment (CYFRA 21-1) and carcinoembryonic antigen (CEA) as tumour markers for non-small cell lung cancer.
    Chantapet P; Riantawan P; Lebnak P; Getngern P
    J Med Assoc Thai; 2000 Apr; 83(4):383-91. PubMed ID: 10808698
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of serum growth factors and tumor markers as prognostic factors for survival in non-small cell lung cancer.
    Nieder C; Andratschke N; Jeremic B; Molls M
    Anticancer Res; 2003; 23(6D):5117-23. PubMed ID: 14981976
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pro-gastrin-releasing peptide (ProGRP)--a useful marker in small cell lung carcinomas.
    Stieber P; Dienemann H; Schalhorn A; Schmitt UM; Reinmiedl J; Hofmann K; Yamaguchi K
    Anticancer Res; 1999; 19(4A):2673-8. PubMed ID: 10470218
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Monitoring of therapy in inoperable lung cancer patients by measurement of CYFRA 21-1, TPA- TP CEA, and NSE.
    Ebert W; Hoppe M; Muley T; Drings P
    Anticancer Res; 1997; 17(4B):2875-8. PubMed ID: 9329552
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pretreatment serum levels of cytokines and cytokine receptors in patients with non-small cell lung cancer, and correlations with clinicopathological features and prognosis. M-CSF - an independent prognostic factor.
    Kaminska J; Kowalska M; Kotowicz B; Fuksiewicz M; Glogowski M; Wojcik E; Chechlinska M; Steffen J
    Oncology; 2006; 70(2):115-25. PubMed ID: 16645324
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum CYFRA 21-1 in advanced stage non-small cell lung cancer: an early measure of response.
    Vollmer RT; Govindan R; Graziano SL; Gamble G; Garst J; Kelley MJ; Christenson RH
    Clin Cancer Res; 2003 May; 9(5):1728-33. PubMed ID: 12738727
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases.
    Schneider J; Philipp M; Velcovsky HG; Morr H; Katz N
    Anticancer Res; 2003; 23(2A):885-93. PubMed ID: 12820318
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of CEA and trophoblastic cell markers by lung carcinoma in association with histological characteristics and serum marker levels.
    Slodkowska J; Szturmowicz M; Rudzinski P; Giedronowicz D; Sakowicz A; Androsiuk W; Zakrzewska-Rowinska E
    Eur J Cancer Prev; 1998 Feb; 7(1):51-60. PubMed ID: 9511851
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Persistently high serum carcinoembryonic antigen levels after surgery indicate poor prognosis in patients with stage I non-small-cell lung cancer.
    Wang CY; Huang MS; Huang MH; Lee HC; Hsu HS
    J Surg Res; 2010 Oct; 163(2):e45-50. PubMed ID: 20638687
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of Cyfra 21-1 as a marker for lung cancer.
    Najemnik C; Mohn-Staudner A; Vetter H; Kokron O; Baumgartner G; Scheiner W; Zwick H; Koderhold G; Alth G; Dudczak R
    Wien Klin Wochenschr; 1996; 108(15):467-72. PubMed ID: 8806188
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clinical value of combined determination of serum and pleural effusion level of CEA,CYFRA21-1, TPS in the diagnosis of lung cancer].
    Huang F; Wang XL; Yang L; Yin BX; Geng Y; Li TT
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2008 Apr; 24(4):370-2. PubMed ID: 18394347
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clinical value of combined detection of serum tumor markers in lung cancer diagnosis].
    Chen F; Li WM; Wang DM; Gao SS; Bao Y; Chen WB; Liu D
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 Sep; 39(5):832-5. PubMed ID: 19024326
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic significance of preoperative serum carcinoembryonic antigen level in lung adenocarcinoma but not squamous cell carcinoma.
    Tomita M; Matsuzaki Y; Edagawa M; Shimizu T; Hara M; Onitsuka T
    Ann Thorac Cardiovasc Surg; 2004 Apr; 10(2):76-80. PubMed ID: 15209547
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preoperative serum carcinoembryonic antigen level is a prognostic factor in women with early non-small-cell lung cancer.
    Hsu WH; Huang CS; Hsu HS; Huang WJ; Lee HC; Huang BS; Huang MH
    Ann Thorac Surg; 2007 Feb; 83(2):419-24. PubMed ID: 17257963
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum tumor marker CYFRA 21-1 in the diagnostics of squamous cell lung cancer--comparison with CEA.
    Berzinec P; Zuffová H; Letkovicová M; Arpásová M
    Neoplasma; 1996; 43(3):159-61. PubMed ID: 8841502
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Early diagnosis and treatment monitoring roles of tumor markers Cyfra 21-1 and TPS in oral squamous cell carcinoma.
    Nagler RM; Barak M; Peled M; Ben-Aryeh H; Filatov M; Laufer D
    Cancer; 1999 Mar; 85(5):1018-25. PubMed ID: 10091783
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of different markers in non-small cell lung cancer: prognostic value of clinical staging, tumour cell detection and tumour marker analysis for tumour progression and overall survival.
    Kasimir-Bauer S; Schleucher N; Weber R; Neumann R; Seeber S
    Oncol Rep; 2003; 10(2):475-82. PubMed ID: 12579292
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.